Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Barbara Klencke
VIEWPOINTS
PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153
In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…
October 11, 20210Comments
Viewpoints_Salom Juethner
VIEWPOINTS
PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro
In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal Allergy Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 20210Comments
Exclusive_Kevin Cammack1_Mark Warren2_2021
EXCLUSIVE
Exclusive Interview with PharmaShots: Kevin Cammack and Mark Warren Share Insight on Lyumjev U-100 Approved for Use in Insulin Pumps
In an interview with PharmaShots, Kevin Cammack, Head of Connected Care, Eli Lilly, and Mark Warren, MD, Director of Endocrine Clinical Trials and Laboratory Services, Physicians East share their views on the US FDA’s approval of rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2…
October 4, 20210Comments
Viewpoints_Ahmet Sezer, Karl Lewis, and Israel Lowy
VIEWPOINTS
PharmaShots Interview: Dr. Ahmet Sezer, Karl Lewis, and Regeneron’s Israel Lowy Share Insights on Libtayo (cemiplimab) for NSCLC & BCC
In an interview with PharmaShots, Dr. Ahmet Sezer, (Professor in the Department of Medical Oncology at Baskent University), Karl Lewis (Professor in the Division of Medical Oncology at the University of Colorado) and Israel Lowy (Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron) shared their views on the EC's approval of Libtayo for…
September 29, 20210Comments
Viewpoints_Dr. Ian Waxman
VIEWPOINTS
PharmaShots Interview: BMS’ Dr. Ian Waxman Shares Insights on the Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC
In an interview with PharmaShots, Dr. Ian Waxman, MD, Development Lead, Gastrointestinal Cancer at BMS shared his views on the EC's approval of Opdivo (nivolumab) + Yervoy (ipilimumab) for the Treatment of dMMR or MSI-H mCRC Shots: The approval is based on P-II CheckMate -142 study evaluating Opdivo + Yervoy in patients with dMMR or MSI-H mCRC whose disease had…
September 28, 20210Comments
Viewpoints_Dr. David Kendall
VIEWPOINTS
PharmaShots Interview: Zealand Pharma’s Dr. David Kendall Shares Insights on Zegalogue for Severe Hypoglycemia in Pediatric and Adult Patients with Diabetes
In an interview with PharmaShots, Dr. David Kendall, Senior Global Medical Advisor at Zealand Pharma shared his views on the availability of Zegalogue in the US for severe hypoglycemia in pediatric and adult patients with diabetes & its availability in both an auto-injector and a prefilled syringe Shots: The company reported the availability of Zegalogue (0.6mg/0.6mL) in the US…
September 27, 20210Comments